Below is Scrip’s regular roundup, including information from Strategic Transactions, of recent technology transfer agreements between companies and academic or other research institutions.
Solidifying a strategy that began with licensing cancer candidate Gem-DHA from privately held CBM BioPharma, Spherix Inc